De PhD y otros demonios. Sandra Bermeo
2009 Apr;80(4):609-14.
37. González-Ruiz A, Haque R, Aguirre A, Castañón G, Hall A, Guhl F, et al. Value of microscopy in the diagnosis of dysentery associated with invasive Entamoeba histolytica. J Clin Pathol. 1994 Mar;47(3):236-9.
38. Petri WA Jr, Singh U. Diagnosis and management of amebiasis. Clin Infect Dis. 1999 Nov;29(5):1117-25.
39. Visser LG, Verweij JJ, Van Esbroeck M, Edeling WM, Clerinx J, Polderman AM. Diagnostic methods for differentiation of Entamoeba histolytica and Entamoeba dispar in carriers: performance and clinical implications in a non-endemic setting. Int J Med Microbiol. 2006 Oct;296(6):397-403.
40. Mirelman D, Nuchamowitz Y, Stolarsky T. Comparison of use of enzyme-linked immunosorbent assay-based kits and PCR amplification of rRNA genes for simultaneous detection of Entamoeba histolytica and E. dispar. J Clin Microbiol. 1997 Sep;35(9):2405-7.
41. Guzmán C, López MC, Reyes P, Gómez JE, Corredor A, Agudelo C. Diferenciación de Entamoeba histolytica y Entamoeba dispar en muestras de materia fecal por detección de adhesina de E. histolytica mediante ELISA. Biomé- dica 2001; 21:167-71.
42. Haque R, Roy S, Siddique A, Mondal U, Rahman SM, Mondal D, et al. Multiplex real-time PCR assay for detection of Entamoeba histolytica, Giardia intestinalis, and Cryptosporidium spp. Am J Trop Med Hyg. 2007 Apr;76(4):713-7.
43. Stark D, van Hal SJ, Matthews G, Harkness J, Marriott D. Invasive amebiasis in men who have sex with men, Australia. Emerg Infect Dis. 2008 Jul;14(7):1141-3.
44. 44. Haque R, Mondal D, Kirkpatrick BD, Akther S, Farr BM, Sack RB, et al. Epidemiologic and clinical characteristics of acute diarrhea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh. Am J Trop Med Hyg. 2003 Oct;69(4):398-405.
45. Pinheiro SM, Carneiro RM, Aca IS, Irmão JI, Morais MA Jr, Coimbra MR, et al. Determination of the prevalence of Entamoeba histolytica and E. dispar in the pernambuco state of northeastern Brazil by a polymerase chain reaction. Am J Trop Med Hyg. 2004 Feb;70(2):221-4.
46. Chacín-Bonilla L. Amebiasis: aspectos clínicos, terapéuticos y de diagnóstico de la infección. Rev Med Chile 2013;141:609-15.
47. Gatti S, Swierczynski G, Robinson F, Anselmi M, Corrales J, Moreira J, et al. Amebic infections due to the Entamoeba histolytica-Entamoeba dispar complex: a study of the incidence in a remote rural area of Ecuador. Am J Trop Med Hyg. 2002 Jul;67(1):123-7.
48. Corredor A, Arciniegas E, Hernández CA. Parasitosis intestinal. Instituto Nacional de Salud, Bogotá, 2000.
49. Gallego ML, Gómez JE, Torres E, Lora F. Prevalencia de Entamoeba histolytica en asentamientos temporales post-terremoto de la ciudad de Armenia. Infectio 2003; 7(4):190-4.
50. Samie A, Barrett LJ, Bessong PO, Ramalivhana JN, Mavhandu LG, Njayou M, et al. Seroprevalence of Entamoeba histolytica in the context of HIV and AIDS: the case of Vhembe district, in South Africa’s Limpopo province. Ann Trop Med Parasitol. 2010 Jan;104(1):55-63.
51. Abdollahi A, Saffar H, Saffar H, Sheikhbahaei S, Rasoulinejad M. Is the evaluation of Entamoeba histolytica infection in HIV-positive patients of any clinical significance? Acta Med Iran. 2015;53(1):46-50.
52. Atías A, Sapunar J. Parodi V, Pérez C, Gabor M, Stagno S, et al. Tratamiento de la amebiasis intestinal crónica con Teclozán. Bol Chil Parasitol 1972; 27(3):119-21.
53. Zuluaga H, Botero D, Vélez H, Castaño A. Estudios terapéuticos y quimioprofilácticos con la droga antiamibiana Win-13.146. Antioquia Med 1971; 21:559-74.
54. Johnson PJ. Metronidazole and drug resistance. Parasitol Today. 1993 May;9(5):183-6.
55. Spillmann R, Ayala SC, Sanchez CE. Double-blind test of metronidazole and tinidazole in the treatment of asymptomatic Entamoeba histolytica and Entamoeba hartmanni carriers. Am J Trop Med Hyg. 1976 Jul;25(4):549-51.
56. Kauser H, Qadir M, Anwar W. Ocular side effect of tinidazole: a rare case report. J Family Med Prim Care. 2014 Oct-Dec;3(4):467-9.
57. Botero D. An overview of the clinical experience of secnidazole in giardiasis and amoebiasis. Drug Invest 1994; 8 (Suppl 1):47-52.
58. Restrepo M, Díaz T, Cuervo C. Valoración de la eficacia y tolerancia del Secnidazol a dosis única en niños con Amebiasis Intestinal Sintomática. Medicina UPB 1996; 15:59-65.
59. Fonte-Galindo L, Fernández-Ferrer M de L, Sánchez-Valdés L, Marín-Iglesias H, Montano-Goodridge I, Maestre-Mesa J. Eficacia antiamebiana del metronidazol demostrada en un estudio realizado en la provincia de Cienfuegos. Rev Cubana Med Trop 2002; 54:101-5.
60. Belkind-Valdovinos U, Belkind-Gerson J, Sánchez.Francia D, Espinoza-Ruiz MM, Lazcano-Ponce L. Evaluación de la nitazoxanida en dosis única y por tres días en parasitosis intestinal. Salud Publ México 2004;46(3):333-40.
61. Rossignol JF, Kabil SM, El-Gohary Y, Younis AM. Nitazoxanide in the treatment of amoebiasis. Trans R Soc Trop Med Hyg. 2007 Oct;101(10):1025-31.
62. Windsor JJ, Macfarlane L. Irritable bowel syndrome: the need to exclude Dientamoeba fragilis. Am J Trop Med Hyg. 2005 May;72(5):501.
63. Stensvold CR, Arendrup MC, Mølbak K, Nielsen HV. The prevalence of Dientamoeba fragilis in patients with suspected enteroparasitic disease in a metropolitan area in Denmark. Clin Microbiol Infect. 2007 Aug;13(8):839-42.
64. Nagata N, Marriott D, Harkness J, Ellis JT, Stark D. Current treatment options for Dientamoeba fragilis infections. Int J Parasitol Drugs Drug Resist. 2012 Sep 3;2:204-15.
65. De Jong MJ, Korterink JJ, Benninga MA, Hilbink M, Widdershoven J, Deckers-Kocken JM. Dientamoeba fragilis and chronic abdominal pain in children: a case-control study. Arch Dis Child. 2014 Dec;99(12):1109-13.
66. Cacciò SM, Sannella AR, Manuali E, Tosini F, Sensi M, Crotti D, et al. Pigs as natural hosts of Dientamoeba fragilis genotypes found in humans. Emerg Infect Dis. 2012 May;18(5):838-41.
67. Tshalaia LE. On a species of Entamoeba detected in sewage effluents. Med Parazit (Moscow) 1941;10:244-52.
68. Dreyer DA. Growth of a strain of Entamoeba histolytica at room temperature. Tex Rep Biol Med. 1961;19:393-6.
69. Clark CG, Diamond LS. The Laredo strain and other ‘Entamoeba histolytica-like’ amoebae are Entamoeba moshkovskii. Mol Biochem Parasitol. 1991 May;46(1):11-8.
70. Haque R, Faruque AS, Hahn P, Lyerly DM, Petri WA Jr. Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. J Infect Dis. 1997 Mar;175(3):734-6.
71. Ali IK, Hossain MB, Roy S, Ayeh-Kumi PF, Petri WA Jr, Haque R, et al. Entamoeba moshkovskii infections in children, Bangladesh. Emerg Infect Dis. 2003 May;9(5):580-4.
72. Zebardast N, Haghighi A, Yeganeh F, Seyyed Tabaei SJ, Gharavi MJ, Fallahi S, et al. Application of Multiplex PCR for Detection and differentiation of Entamoeba histolytica, Entamoeba dispar and Entamoeba moshkovskii. Iran J Parasitol. 2014 Oct-Dec;9(4):466-73.
73. Burrows RB. Morphological differentiation of Entamoeba hartmanni and E. polecki from E. histolytica. Am J Trop Med Hyg. 1959 Sep;8:583-9.
74. Desowitz RS, Barnish G. Entamoeba polecki and other intestinal protozoa in Papua New Guinea